All Updates

All Updates

icon
Filter
FDA approval
BMS' Breyanzi receives FDA accelerated approval for follicular lymphoma
Cell & Gene Therapy
May 15, 2024
This week:
Funding
GrayMatter Robotics raises USD 45 million in Series B funding to accelerate AI-powered robotics solutions
Smart Factory
Yesterday
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Logistics Tech
Yesterday
Funding
Vecna Robotics raises USD 100 million in Series C funding; appoints new COO
Smart Factory
Yesterday
Funding
FairNow raises USD 3.5 million to advance AI governance solutions
Generative AI Infrastructure
Yesterday
Partnerships
Gravitics develops testing gauntlet for larger spacecraft in collaboration with NASA
Space Travel and Exploration Tech
Yesterday
M&A
knownwell acquires Alfie Health to integrate AI in primary and obesity care services
Telehealth
Yesterday
Funding
Pomelo Care raises USD 46 million in Series B funding to expand virtual maternal care
Telehealth
Yesterday
Funding
Isar Aerospace raises EUR 65 million, backed by NATO Innovation Fund
Space Travel and Exploration Tech
Yesterday
Product updates
Beyond Meat releases new Beyond Sausage, expanding its Beyond IV product line
Plant-based Meat
Yesterday
Product updates
Funding
SurrealDB raises USD 20 million in Series A; launches beta version of Surreal Cloud
Data Infrastructure & Analytics
Yesterday
Cell & Gene Therapy

Cell & Gene Therapy

May 15, 2024

BMS' Breyanzi receives FDA accelerated approval for follicular lymphoma

FDA approval

  • Bristol Myers Squibb (BMS) has received accelerated approval from the FDA for its one-time CAR T therapy, Breyanzi, for adult patients with relapsed or refractory follicular lymphoma. Breyanzi is used on patients with at least two previous systemic therapies.

  • According to BMS, Breyanzi demonstrates a significant overall response rate of 95.7% and a complete response rate of 73.4%. The drug has also showcased a consistent safety profile throughout the trials, providing potential for lasting remission with a one-time infusion and safety profile for administration and monitoring in the inpatient and outpatient setting.

  • Breyanzi is approved in the US for treating relapsed or refractory large B-cell lymphoma (LBCL), with accelerated approval for chronic lymphocytic leukemia or small lymphocytic lymphoma after prior therapies. It's also approved in Japan, the EU, and Switzerland for different stages of LBCL treatment, including second-line and multiple relapse scenarios.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.